The Influence of Vascular Burden, Amyloid Plaque and Tau Protein in Patients With Vascular Cognitive Impairment and Dementia With Tauopathy
Vascular Cognitive Impairment, Alzheimer's Disease, Fronto-temporal Dementia
About this trial
This is an interventional diagnostic trial for Vascular Cognitive Impairment, Alzheimer's Disease, Fronto-temporal Dementia focused on measuring Vascular cognitive impairment, Alzheimer's disease, fronto-temporal dementia, amyloid plaque, tau protein
Eligibility Criteria
Inclusion Criteria:
Inclusion criteria for VCI (Group A, n=80)
- Males or females with age >= 20 years old.
- Patients fulfill the AHA/ASA criteria for vascular cognitive impairment.
- Provision of signed informed consent from the subject and the subject's legally authorized representative or caregiver (if applicable).
- The subject has an appropriate caregiver capable of accompanying the subject, if necessary.
Inclusion criteria for AD / MCI (Group B, n=80)
- Males or females with age >= 20 years old.
- Patients fulfill the National Institute on Aging (NIA) - Alzheimer's Association Diagnostic Guidelines.
- Provision of signed informed consent from the subject and the subject's legally authorized representative or caregiver (if applicable).
- The subject has an appropriate caregiver capable of accompanying the subject, if necessary.
Inclusion criteria for FTD (Group C, n=30)
- Males or females with age >= 20 years old.
- Patients fulfill the criteria of probable FTD.
- Provision of signed informed consent from the subject and the subject's legally authorized representative or caregiver (if applicable).
- The subject has an appropriate caregiver capable of accompanying the subject, if necessary.
Inclusion criteria for normal control (Group D, n=30)
- Males or females with age >= 20 years old.
- Provision of signed informed consent.
Exclusion Criteria:
- Life expectancy less than 1 year.
- Clinically significant abnormal laboratory values (such as AST/ALT >= 3X of upper normal limits).
- Clinically significant or unstable medical or psychiatric illness.
- Epilepsy history.
- Cognitive impairment resulting from trauma or brain damage.
- Substance abuse or alcoholism in the past 3 months.
- Stroke history within the recent 3 months.
Sites / Locations
- Department of Neurology, Chang-Gung memorial HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Other
Other
PMPBB3
AV45
Primary endpoint(s): A. To determine the distribution patterns of cerebral amyloid plaques and Tau protein among AD/MCI, VCI and FTP patients as well as normal controls. Secondary endpoints: A. To correlate vascular burden, [18F]AV45 and [18F]MNI-958(PMPBB3) retention with clinical presentation and cognitive performance among different groups of subjects B. To determine the impacts of vascular burden, [18F]AV45 and [18F]MNI-958(PMPBB3) retention changes on cognitive trajectory over the 18-month follow-up period.
Primary endpoint(s): A. To determine the distribution patterns of cerebral amyloid plaques and Tau protein among AD/MCI, VCI and FTP patients as well as normal controls. Secondary endpoints: A. To correlate vascular burden, [18F]AV45 and [18F]MNI-958(PMPBB3) retention with clinical presentation and cognitive performance among different groups of subjects B. To determine the impacts of vascular burden, [18F]AV45 and [18F]MNI-958(PMPBB3) retention changes on cognitive trajectory over the 18-month follow-up period.